# A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

> **NCT06051695** · PHASE1,PHASE2 · RECRUITING · sponsor: **A2 Biotherapeutics Inc.** · enrollment: 474 (estimated)

## Conditions studied

- Solid Tumor, Adult
- Colorectal Cancer
- NSCLC
- Non Small Cell Lung Cancer
- NSCLC, Recurrent
- Non-Small Cell Squamous Lung Cancer
- Pancreas Cancer
- Pancreatic Neoplasm
- Colorectal Adenocarcinoma
- CRC
- Colon Cancer
- Rectal Cancer
- Cancer
- Ovarian Cancer
- Ovarian Neoplasms
- Mesothelioma
- Mesothelioma, Malignant
- Ovary Cancer
- Lung Cancer
- MESOM

## Interventions

- **BIOLOGICAL:** A2B694
- **BIOLOGICAL:** A2B543
- **DIAGNOSTIC_TEST:** xT CDx with HLA-LOH Assay

## Key facts

- **NCT ID:** NCT06051695
- **Lead sponsor:** A2 Biotherapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-03
- **Primary completion:** 2028-06
- **Final completion:** 2029-06
- **Target enrollment:** 474 (ESTIMATED)
- **Last updated:** 2026-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06051695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06051695, "A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06051695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*